IN202141039393A - - Google Patents

Download PDF

Info

Publication number
IN202141039393A
IN202141039393A IN202141039393A IN202141039393A IN202141039393A IN 202141039393 A IN202141039393 A IN 202141039393A IN 202141039393 A IN202141039393 A IN 202141039393A IN 202141039393 A IN202141039393 A IN 202141039393A IN 202141039393 A IN202141039393 A IN 202141039393A
Authority
IN
India
Application number
IN202141039393A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to IN202141039393A priority Critical patent/IN202141039393A/en
Priority to CA3229559A priority patent/CA3229559A1/en
Priority to US18/686,936 priority patent/US20240352039A1/en
Priority to PCT/IN2022/050772 priority patent/WO2023031960A1/en
Publication of IN202141039393A publication Critical patent/IN202141039393A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D515/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995Pyrazines or piperazines forming part of bridged ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
IN202141039393A 2021-08-31 2021-08-31 IN202141039393A (https=)

Priority Applications (4)

Application Number Priority Date Filing Date Title
IN202141039393A IN202141039393A (https=) 2021-08-31 2021-08-31
CA3229559A CA3229559A1 (en) 2021-08-31 2022-08-30 Novel crystalline polymorph of lurbinectedin and improved process for the preparation of lurbinectedin
US18/686,936 US20240352039A1 (en) 2021-08-31 2022-08-30 Novel crystalline polymorph of lurbinectedin and improved process for the preparation of lurbinectedin
PCT/IN2022/050772 WO2023031960A1 (en) 2021-08-31 2022-08-30 Novel crystalline polymorph of lurbinectedin and improved process for the preparation of lurbinectedin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN202141039393A IN202141039393A (https=) 2021-08-31 2021-08-31

Publications (1)

Publication Number Publication Date
IN202141039393A true IN202141039393A (https=) 2023-03-03

Family

ID=85412216

Family Applications (1)

Application Number Title Priority Date Filing Date
IN202141039393A IN202141039393A (https=) 2021-08-31 2021-08-31

Country Status (4)

Country Link
US (1) US20240352039A1 (https=)
CA (1) CA3229559A1 (https=)
IN (1) IN202141039393A (https=)
WO (1) WO2023031960A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025059336A1 (en) * 2023-09-13 2025-03-20 Navinta, Llc An improved process for preparation of lurbinectedin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119243D0 (en) * 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
MA56827B2 (fr) * 2019-11-21 2023-09-27 Pharma Mar Sa Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025059336A1 (en) * 2023-09-13 2025-03-20 Navinta, Llc An improved process for preparation of lurbinectedin

Also Published As

Publication number Publication date
US20240352039A1 (en) 2024-10-24
WO2023031960A1 (en) 2023-03-09
CA3229559A1 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
IN202141039393A (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)